print_label | resize_label
 

Even after an initial response, the majority of patients with metastatic EGFRm NSCLC will progress on an EGFR TKI1,2

 

EGFR TKIs are a standard first-line therapy option for patients with metastatic EGFRm NSCLC

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend EGFR TKIs as a first-line treatment option for patients with metastatic EGFRm NSCLC3

Approximately 30% of patients with EGFR mutation-positive NSCLC develop CNS metastases after an initial response to an EGFR TKI4-6

Most patients with metastatic EGFRm NSCLC will experience disease progression on first-line EGFR TKIs7-9

Even after an initial tumor response, the median time to progression with first-line EGFR TKIs is approximately 8-14 months10

At progression on an EGFR TKI, treatment options were previously limited

    Previous standard of care included continued EGFR TKI therapy or chemotherapy2

Nearly 2 out of 3 cases of progression with first-generation EGFR TKIs are related to the acquired EGFR T790M mutation1

 
EGFR TKI Resistance Chart EGFR TKI Resistance Chart EGFR TKI Resistance Chart
 

Adapted from Yu HA, et al. Clin Cancer Res. 2013.

Study of 155 patients with radiographic progression following a response or durable stable disease with first-generation EGFR TKI therapy. Other rare mechanisms of acquired resistance may include BRAF, FGFR, and PIK3CA mutations, and transformation to small-cell histology.11,12

X


X